The invention is concerned with novel pyrazol derivatives of formula (I),
wherein
R
1
, R
2
, R
3
, R
4
, X and Y are as defined herein, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor and/or CCR-5 receptor and can be used as medicaments.
FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
申请人:Genfleet Therapeutics (Shanghai) Inc.
公开号:EP4159739A1
公开(公告)日:2023-04-05
Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity, and reduced toxic side effects.